Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women
A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17β-estradiol system, at three different dosages (25, 50 and 75 μg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1999
|
| _version_ | 1826287434870030336 |
|---|---|
| author | Cooper, C Stakkestad, J Radowicki, S Hardy, P Pilate, C Dain, M Delmas, P Grp, I |
| author_facet | Cooper, C Stakkestad, J Radowicki, S Hardy, P Pilate, C Dain, M Delmas, P Grp, I |
| author_sort | Cooper, C |
| collection | OXFORD |
| description | A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17β-estradiol system, at three different dosages (25, 50 and 75 μg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At 2 years, the difference from placebo in percentage change from baseline of L1-4 lumbar spine bone mineral density (BMD) (assessed by dual-energy X-ray absorptiometry) was 4.7% ± 0.7% with estradiol 25 μg/day, 7.3% ± 0.7% with estradiol 50 μg/day and 8.7% ± 0.7% with estradiol 75 μg/day (all values mean ± SEM). There were also significant increases in femoral neck, trochanter and total hip BMD with all doses of estradiol compared with placebo. Additionally, most patients had a significant gain (increase greater than 2.08%) in lumbar spine bone mass compared with placebo. Patients who received estradiol also experienced clinically significant and dose-related decreases in total serum osteocalcin, serum bone alkaline phosphatase and urinary C-telopeptide, with all three markers of bone turnover returning to premenopausal levels. Estradiol was well tolerated during the 2-year treatment period. Transdermal estradiol is effective and well tolerated at dosages between 25-75 μg/day in the prevention of bone loss in postmenopausal women; 25 μg/day offers an effective option for those women who cannot tolerate higher doses. |
| first_indexed | 2024-03-07T01:58:37Z |
| format | Journal article |
| id | oxford-uuid:9c970a65-e113-4f7d-a2c4-77e5129050e1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:58:37Z |
| publishDate | 1999 |
| record_format | dspace |
| spelling | oxford-uuid:9c970a65-e113-4f7d-a2c4-77e5129050e12022-03-27T00:37:04ZMatrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal womenJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9c970a65-e113-4f7d-a2c4-77e5129050e1EnglishSymplectic Elements at Oxford1999Cooper, CStakkestad, JRadowicki, SHardy, PPilate, CDain, MDelmas, PGrp, IA total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17β-estradiol system, at three different dosages (25, 50 and 75 μg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At 2 years, the difference from placebo in percentage change from baseline of L1-4 lumbar spine bone mineral density (BMD) (assessed by dual-energy X-ray absorptiometry) was 4.7% ± 0.7% with estradiol 25 μg/day, 7.3% ± 0.7% with estradiol 50 μg/day and 8.7% ± 0.7% with estradiol 75 μg/day (all values mean ± SEM). There were also significant increases in femoral neck, trochanter and total hip BMD with all doses of estradiol compared with placebo. Additionally, most patients had a significant gain (increase greater than 2.08%) in lumbar spine bone mass compared with placebo. Patients who received estradiol also experienced clinically significant and dose-related decreases in total serum osteocalcin, serum bone alkaline phosphatase and urinary C-telopeptide, with all three markers of bone turnover returning to premenopausal levels. Estradiol was well tolerated during the 2-year treatment period. Transdermal estradiol is effective and well tolerated at dosages between 25-75 μg/day in the prevention of bone loss in postmenopausal women; 25 μg/day offers an effective option for those women who cannot tolerate higher doses. |
| spellingShingle | Cooper, C Stakkestad, J Radowicki, S Hardy, P Pilate, C Dain, M Delmas, P Grp, I Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women |
| title | Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women |
| title_full | Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women |
| title_fullStr | Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women |
| title_full_unstemmed | Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women |
| title_short | Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women |
| title_sort | matrix delivery transdermal 17 beta estradiol for the prevention of bone loss in postmenopausal women |
| work_keys_str_mv | AT cooperc matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomen AT stakkestadj matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomen AT radowickis matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomen AT hardyp matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomen AT pilatec matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomen AT dainm matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomen AT delmasp matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomen AT grpi matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomen |